THTX_OUT_1 [2025-03-26 14:44:53 -0400] 2125 Bytes | 612 tokens | Cum: 612 tkns (7.65% of 8k)
==========================================================================

Listen up, partner—it's 2:44:51 PM on Wed Mar 26, 2025 -0400, and I’m revved up about Theratechnologies (THTX), climbing from 1.54 to 1.855. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for Theratechnologies:

C1 - Mar-25-25 05:45PM - Theratechnologies Receives FDA Approval for EGRIFTA WR (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
C2 - Mar-12-25 07:30AM - Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
C3 - Mar-12-25 07:30AM 07:30AM - Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
C4 - Feb-27-25 02:09AM - Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ...
C5 - Feb-26-25 07:54AM - Theratechnologies: Fiscal Q4 Earnings Snapshot
C6 - Feb-26-25 07:54AM 07:30AM - Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024
C7 - Feb-25-25 11:02AM - Theratechnologies Inc (TSX:TH) Q4 2024: Everything You Need to Know Ahead of Earnings
C8 - Feb-14-25 07:30AM - Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Theratechnologies (THTX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

THTX_OUT_3 [2025-03-26 14:44:55 -0400] 1049 Bytes | 333 tokens | Cum: 947 tkns (11.84% of 8k)
==========================================================================

Showing C1 (chunk 1 of 9): C1:
**Theratechnologies Receives FDA Approval for EGRIFTA WR (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy**
Date: Mar-25-25 05:45PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/25/3049233/0/en/Theratechnologies-Receives-FDA-Approval-for-EGRIFTA-WR-Tesamorelin-F8-to-Treat-Excess-Visceral-Abdominal-Fat-in-Adults-with-HIV-and-Lipodystrophy.html

March 25, 2025 17:45 ET| Source:TheratechnologiesTheratechnologies

New, improved formulation set to replace EGRIFTA SV®

MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental Biologics License Application (sBLA) for the F8 formulation of t

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

THTX_OUT_5 [2025-03-26 14:44:57 -0400] 1051 Bytes | 259 tokens | Cum: 1208 tkns (15.10% of 8k)
==========================================================================

Showing C1 (chunk 2 of 9): esamorelin for injection. The Company will commercialize the new formulation under the tradenameEGRIFTA WR™.

Tesamorelin for injection is the only medication approved in the U.S. for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy. The new formulation,EGRIFTA WR™,is a daily injectable but only needs weekly reconstitution. It requires less than half the administration volume as the current F4 formulation, sold in the U.S. asEGRIFTA SV®, which is reconstituted daily. Pharmacokinetic studies have shown bioequivalence ofEGRIFTA WR™to the original F1 formulation of tesamorelin for injection (previously sold under the trade nameEGRIFTA®). The most commonly reported adverse reactions ofEGRIFTA WR™include arthralgia, injection site reactions, pain in extremity, peripheral edema, and myalgia.

“We are pleased to offer this improved, more convenient version of tesa

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

THTX_OUT_7 [2025-03-26 14:44:58 -0400] 1018 Bytes | 306 tokens | Cum: 1516 tkns (18.95% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-26T10:18:34Z - US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From ...
A2 - 2025-03-26T09:00:09Z - Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - AquaBoun...
A3 - 2025-03-26T02:54:00Z - THTX : FDA Oks EGRIFTA WR To Treat Excess Visceral Abdominal Fat In Adults With HIV & Lipodystrophy...
A4 - 2025-03-25T22:39:31Z - Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Ab...
A5 - 2025-03-25T21:58:06Z - FDA approves new tesamorelin formulation by Theratechnologies By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

THTX_OUT_9 [2025-03-26 14:45:00 -0400] 1038 Bytes | 260 tokens | Cum: 1778 tkns (22.23% of 8k)
==========================================================================

Showing A1 (chunk 1 of 7): A1:
**US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert - CISO Global (NASDAQ:CISO)**Date: 2025-03-26Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/25/03/44489584/us-stocks-likely-to-open-lower-after-three-day-advance-market-is-looking-more-balanced-and-gone-from-above-trend-to-on-trend-says-expertU.S. stock futures were trading lower on Wednesday, after advancing for three consecutive sessions. Futures of major benchmark indices were lower in premarket trading.

Investors are reacting cautiously to President Donald Trump's mixed tariff signals. While stocks rallied on hints of potential duty reductions, Trump also announced impending tariffs on pharma and auto, along with secondary tariffs on Venezuelan oil and gas buyers. The volatility reflect

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

THTX_OUT_11 [2025-03-26 14:45:04 -0400] 1046 Bytes | 334 tokens | Cum: 2114 tkns (26.42% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-26T10:18:34Z - US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert
B2 - 2025-02-14T00:45:00Z - Theratechnologies Resumes Distribution of EGRIFTA SV®
B3 - 2025-02-14T00:45:00Z - Theratechnologies reprend la distribution d’EGRIFTA SV(MD)
B4 - 2025-01-10T13:00:00Z - World Orphan Drug Alliance expands to Canada and full LATAM region, completing the first truly global commercialization offering
B5 - 2024-09-17T21:00:00Z - Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
B6 - 2024-09-17T21:00:00Z - Theratechnologies annonce un risque d’interruption temporaire de l’approvisionnement d’EGRIFTA SVᴹᴰ au début de 2025

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

THTX_OUT_13 [2025-03-26 14:45:07 -0400] 724 Bytes | 185 tokens | Cum: 2301 tkns (28.76% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/25/03/44489584/us-stocks-likely-to-open-lower-after-three-day-advance-market-is-looking-more-balanced-and-gone-from-above-trend-US stock futures are trading lower after a three-day advance, as investors react cautiously to President Trump's mixed tariff signals. The market is looking more balanced, having moved from 'above-trend to on-trend', according to an expert.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

THTX_OUT_15 [2025-03-26 14:45:09 -0400] 238 Bytes | 59 tokens | Cum: 2422 tkns (30.28% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

THTX_OUT_17 [2025-03-26 14:45:22 -0400] 3287 Bytes | 835 tokens | Cum: 3260 tkns (40.75% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+---------------------+----------------------+------------------------+----------------------+------------------------+
| Volume: 47,548,953 | SMA50: 11.81% | Market Cap: 44.53M | Option/Short: Yes / No | Sales past 5Y: 6.40% | Sales Surprise: 10.23% |
+---------------------+---------------------+----------------------+------------------------+----------------------+------------------------+
| Avg Volume: 192.53K | SMA200: 27.44% | Shs Outstand: 45.98M | Short Float: 0.25% | Employees: 105 | EPS Surprise: -420.00% |
+---------------------+---------------------+----------------------+------------------------+----------------------+------------------------+
| Rel Volume: 317.31 | Perf Week: 18.71% | Shs Float: 19.10M | Short Ratio: 0.25 | Debt/Eq: - | P/E: - |
+---------------------+---------------------+----------------------+------------------------+----------------------+------------------------+
| RSI (14): 63.84 | Perf Month: 1.38% | Inst Own: 57.43% | Short Interest: 0.05M | Sales Y/Y TTM: 5.02% | Earnings: Feb 26 BMO |
+---------------------+---------------------+----------------------+------------------------+----------------------+------------------------+
| ATR (14): 0.13 | Perf Quarter: 2.79% | Insider Own: 21.08% | Beta: 1.07 | ROE: - | |
+---------------------+---------------------+----------------------+------------------------+----------------------+------------------------+
| SMA20: 15.85% | Index: - | Insider Trans: 0.00% | Sales Q/Q: 6.61% | ROI: -50.47% | |
+---------------------+---------------------+----------------------+------------------------+----------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.84
Average Volume: 2394330.0
30-Day High: 1.855
30-Day Low: 1.5
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

THTX_OUT_19 [2025-03-26 14:45:25 -0400] 676 Bytes | 167 tokens | Cum: 3657 tkns (45.71% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

THTX_IN_21 [2025-03-26 14:45:25 -0400] 126 Bytes | 29 tokens | Cum: 3714 tkns (46.42% of 8k)
==========================================================================

====================================
[2025-03-26 11:45:25] # Analysis Completed
Elapsed Time: 34.78 seconds